# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- New patent would extend coverage and expand potential value of Virios' antiviral pipeline globally –- Active Long-COVID c...
Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $...
Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing...
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow ...
Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal L...